Iwnms 2004
DOI: 10.1007/3-540-29194-6_25
|View full text |Cite
|
Sign up to set email alerts
|

151Eu Mössbauer Spectroscopy in La0.48Eu0.29Ca0.33MnO3

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
9
1
3

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(13 citation statements)
references
References 15 publications
0
9
1
3
Order By: Relevance
“…In second step, this polysiloxane rubber was copolymerized with acrylic monomers. This hybrid latex showed a better impact-resistance compared to non-hybrid latexes when it was formulated in sealants [12]. Inverted core-shell morphology was obtained when polysiloxane was used in second step [13].…”
Section: Introductionmentioning
confidence: 98%
“…In second step, this polysiloxane rubber was copolymerized with acrylic monomers. This hybrid latex showed a better impact-resistance compared to non-hybrid latexes when it was formulated in sealants [12]. Inverted core-shell morphology was obtained when polysiloxane was used in second step [13].…”
Section: Introductionmentioning
confidence: 98%
“…, which is the lowest reported value [10]. Semiquantitative method using GCE was also applied for the determination of benzocaine together with structurally similar compounds existing in the state of solid microparticles [11].…”
mentioning
confidence: 99%
“…The varying recystallization conditions such as rate of stirring and cooling, antisolvent addition, refluxing/heating, drying under vacuum, and presence of impurities, along with solvents and/or their mixtures with varying polarity have yielded different forms of efavirenz. The patent literature till date reveals 23 different polymorphic forms of efavirenz, one monohydrate and an amorphous form although there is some ambiguity about the actual number of solid forms (polymorphs and solvates) of this API (Radesca et al, 1999(Radesca et al, , 2004Sharma et al, 2006;Khanduri et al, 2006;Reddy et al, 2006;Dova, 2008). In these patents, inventors have claimed novel solid forms of efavirenz based on XRPD and DSC analysis.…”
Section: Efavirenzmentioning
confidence: 99%